Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theriva Biologics, Inc.SYN · Entity 7919 | Chief Medical Officer | December 20, 2017 | December 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theriva Biologics, Inc.
Report date December 20, 2017 · Filed December 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2024-12-19 | Direct | 410,000 |
Reported balance
After 2017-12-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 410,000 · Balance 410,000 F1: These options will vest monthly on a pro rata basis over 36 consecutive months. |
Filing footnotes · ownership attribution and instrument terms
F1: These options will vest monthly on a pro rata basis over 36 consecutive months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2017 Filed Dec 21, 2017 22:20 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 410,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001144204-17-064829 · tv481806_4.xml · derivative · entry 1 Sliman Joseph A. · CIK 0001694213 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2024-12-19 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 22:08 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 188,927 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001144204-17-002734 · v457073_4.xml · derivative · entry 1 Sliman Joseph A. · CIK 0001694213 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,927 Underlying: Common Stock · 188,927 shares Expires 2024-01-16 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.